Equities

Seres Therapeutics Inc

Seres Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6639
  • Today's Change-0.028 / -4.02%
  • Shares traded3.47m
  • 1 Year change-34.59%
  • Beta1.9708
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.

  • Revenue in USD (TTM)374.00k
  • Net income in USD-162.11m
  • Incorporated2010
  • Employees233.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Anixa Biosciences Inc0.00-12.36m107.16m4.00--4.92-----0.3906-0.39060.000.67720.00----0.00-50.54-59.69-52.50-62.61-------6,040.10----0.00-----28.3627.83------
Immunic Inc0.00-96.90m110.80m77.00--2.69-----1.24-1.240.000.45760.00----0.00-147.12-72.09-213.91-80.11------------0.00------22.25---10.97--
X4 Pharmaceuticals Inc563.00k17.63m111.75m93.007.741.186.19198.490.08570.08570.00280.56160.0029--0.67266,053.769.18-61.5310.59-69.2052.40--3,131.79-13,288.936.04--0.4427-------4.93--12.03--
Cue Biopharma Inc8.30m-46.96m112.59m53.00--4.21--13.57-0.9743-0.97430.17180.44450.1437--5.56156,528.30-81.32-57.45-113.52-68.41-----566.02-810.87----0.2242--340.8836.884.30------
Bioatla Inc0.00-104.56m114.58m65.00--3.65-----2.18-2.180.000.64910.00----0.00-84.23-48.72-106.06-57.35-------6,651.71----0.00-------15.95---37.01--
Karyopharm Therapeutics Inc148.44m-87.48m114.93m325.00------0.7743-0.7906-0.79061.17-1.270.64621.584.26456,744.60-38.08-53.02-52.09-65.8595.8597.18-58.93-125.152.93-5.252.53---7.0336.9313.43------
Fennec Pharmaceuticals Inc48.89m2.74m116.55m36.00109.51--42.622.380.03890.03891.75-0.04971.181.216.63--6.62-73.437.70-84.3295.55--5.59-383.287.751.871.05--1,284.50--32.34------
Invivyd Inc2.26m-203.84m116.76m94.00--0.8302--51.57-1.80-1.800.01991.180.0092--1.1324,085.11-82.73---96.25--96.11---9,003.40--4.57--0.00------17.68------
Seres Therapeutics Inc374.00k-162.11m117.73m233.00------314.78-1.18-1.180.0027-0.57420.001--0.02861,605.15-44.53-41.51-59.82-54.13-----43,343.58-170.140.889-17.646.65--1,672.2434.9154.54--32.72--
PDS Biotechnology Corp0.00-40.68m119.66m25.00--3.87-----1.23-1.230.000.84060.00----0.00-65.48-51.63-80.82-59.00-----------21.590.4409-------5.11------
Fractyl Health Inc119.00k-65.88m120.30m102.00--1.70--1,010.90-1.37-1.370.00251.480.00131.023.051,166.67-59.97---67.93--41.18---46,620.17--7.46--0.2862-------48.15------
Fibrobiologics Inc0.00-19.47m121.30m10.00---------0.939-0.9390.00-0.0730.00----0.00-171.13---333.35-----------------------272.15------
Coya Therapeutics Inc9.55m-10.10m122.47m8.00--3.16--12.82-0.7726-0.77260.75892.320.3512----1,194,290.00-37.13---40.92-------105.71------0.00------34.77------
Century Therapeutics Inc2.69m-129.89m124.99m152.00--0.6352--46.55-1.86-1.860.03722.310.0068----17,664.47-33.04---34.83-------4,837.73------0.00---57.01---4.38------
Leap Therapeutics Inc0.00-60.34m125.12m54.00--1.90-----2.00-2.000.001.720.00----0.00-67.81-80.06-80.19-95.03-------7,900.37----0.00-------49.12------
Data as of Nov 12 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

25.99%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 202422.72m14.91%
The Vanguard Group, Inc.as of 30 Jun 20246.25m4.10%
Tang Capital Management LLCas of 30 Jun 20242.41m1.58%
Millennium Management LLCas of 30 Jun 20241.78m1.17%
BlackRock Fund Advisorsas of 30 Jun 20241.68m1.10%
Susquehanna Financial Group LLLPas of 30 Jun 20241.20m0.79%
Geode Capital Management LLCas of 30 Jun 20241.13m0.74%
Hudson Bay Capital Management LPas of 30 Jun 20241.00m0.66%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024721.76k0.47%
Jane Street Capital LLCas of 30 Jun 2024707.07k0.46%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.